32 related articles for article (PubMed ID: 24403494)
1. Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications.
Du P; Li G; Wu L; Huang M
Front Immunol; 2022; 13():1065379. PubMed ID: 36713431
[TBL] [Abstract][Full Text] [Related]
2. RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.
Fujimoto D; Goi T; Koneri K; Hirono Y
Oncotarget; 2018 Mar; 9(20):15208-15218. PubMed ID: 29632637
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy.
Karageorgopoulou S; Kostakis ID; Gazouli M; Markaki S; Papadimitriou M; Bournakis E; Dimopoulos MA; Papadimitriou CA
BMC Cancer; 2017 Jun; 17(1):451. PubMed ID: 28659181
[TBL] [Abstract][Full Text] [Related]
4. High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.
Du P; Wang Y; Chen L; Gan Y; Wu Q
Oncol Lett; 2016 Aug; 12(2):857-862. PubMed ID: 27446360
[TBL] [Abstract][Full Text] [Related]
5. DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis.
Vici P; Buglioni S; Sergi D; Pizzuti L; Di Lauro L; Antoniani B; Sperati F; Terrenato I; Carosi M; Gamucci T; Dattilo R; Bartucci M; Vincenzoni C; Mariani L; Vizza E; Sanguineti G; Gadducci A; Vitale I; Barba M; De Maria R; Mottolese M; Maugeri-Saccà M
PLoS One; 2016; 11(3):e0149872. PubMed ID: 26930412
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR and molecules downstream to PI3K/Akt, Raf-1-MEK-1-MAP (Erk1/2), and JAK (STAT3) pathways in invasive lung adenocarcinomas resected at a single institution.
Torres AF; Nogueira C; Magalhaes J; Costa IS; Aragao A; Gomes Neto A; Martins F; Tavora F
Anal Cell Pathol (Amst); 2014; 2014():352925. PubMed ID: 25763322
[TBL] [Abstract][Full Text] [Related]
7. ERCC1, RRM1 and TUBB3 mRNA expression on the tumor response and overall survival of non-small cell lung cancer treated with platinum-based chemotherapy.
Qiao H; Huang X; Guo H; Liu Y; Yue C
Pak J Med Sci; 2014; 30(6):1403-8. PubMed ID: 25674147
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
9. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation.
Muallem MZ; Marnitz S; Richter R; Köhler C; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):401-6. PubMed ID: 24403494
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and TUBB3 in locally advanced cervical squamous cell cancer and its correlation with different therapeutic regimens.
Zwenger AO; Grosman G; Iturbe J; Leone J; Vallejo CT; Leone JP; Verdera PP; Pérez JE; Leone BA
Int J Biol Markers; 2015 Jul; 30(3):e301-14. PubMed ID: 26165688
[TBL] [Abstract][Full Text] [Related]
12. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis.
Doll CM; Aquino-Parsons C; Pintilie M; Klimowicz AC; Petrillo SK; Milosevic M; Craighead PS; Clarke B; Lees-Miller SP; Fyles AW; Magliocco AM
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):721-7. PubMed ID: 22836058
[TBL] [Abstract][Full Text] [Related]
13. ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.
De Dosso S; Zanellato E; Nucifora M; Boldorini R; Sonzogni A; Biffi R; Fazio N; Bucci E; Beretta O; Crippa S; Saletti P; Frattini M
Cancer Chemother Pharmacol; 2013 Jul; 72(1):159-65. PubMed ID: 23645290
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin 7 as a predictive factor for response to concommitant radiochemotherapy for locally advanced cervical cancer: a preliminary study.
Lambaudie E; Chereau E; Pouget N; Thomassin J; Minsat M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G
Anticancer Res; 2014 Jan; 34(1):177-81. PubMed ID: 24403459
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
